Day: March 6, 2023

Denver, CO, March 06, 2023 (GLOBE NEWSWIRE) — Intrepid Potash, Inc. (NYSE:IPI) (“Intrepid”, the “Company”, “we”, “us”, “our”) today reports its financial results for the fourth quarter and full-year of 2022. Key Financial & Operational Highlights for Fourth Quarter and Full-Year 2022Total sales of $66.7 million in the fourth quarter and $337.6 million for the full-year 2022, as potash and Trio® average net realized sales prices increased to $713 and $479 per ton, respectively. Net income of $4.0 million (or $0.30 per diluted share) and $72.2 million (or $5.37 per diluted share) in the fourth quarter and full-year 2022 respectively, and adjusted net income(1) of $11.0 million and $80.4 million, respectively. Adjusted EBITDA(1) of $23.1 million for the fourth quarter,...

Double-digit, year-over-year growth drives a record 2022 DALLAS, March 06, 2023 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), a leading private markets solutions provider, today reported financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights:Fee Paying Assets Under Management: $21.2 billion, a 23% increase year over year. Revenue: $58.3 million, a 28% increase year over year. GAAP Net Income: $4.8 million, a 221% increase year over year. Adjusted EBITDA: $30.8 million, a 17% increase year over year. Adjusted Net Income: $27.3 million, a 24% increase year over year. Fully diluted GAAP EPS: $.04, a 104% increase year over year. Fully diluted ANI per share: $.22, a 22% increase year over year.Fiscal Year End 2022 Financial Highlights:Revenue: $198.4 million, a 32% increase...

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, United Kingdom, March 06, 2023 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. “We are excited to advance our Kv7 program forward with ETX-123 as the lead candidate,” said Andrew Levin, M.D., Ph.D., Executive Chairman of Eliem Therapeutics. “Our Kv7...

WeightWatchers announces agreement to acquire Sequence, a digital health platform for clinical weight management Fourth Quarter 2022End of Period Subscribers of 3.5 million Revenues of $223.9 million Operating Loss of $50.8 million primarily due to $57.6 million in non-cash intangible impairment charges for Franchise Rights Acquired and Goodwill; Adjusted operating income of $24.2 million excluding the impact of such impairment charges and the net impact of restructuring chargesFull Year Fiscal 2022Revenues of $1.04 billion Operating Loss of $283.0 million primarily due to $396.7 million in non-cash intangible impairment charges for Franchise Rights Acquired and Goodwill; Adjusted operating income of $153.5 million excluding the impact of such impairment charges and the net impact of restructuring chargesQ1 2023 GuidanceRevenues...

Quarterly revenue of $71.3 million, representing a 2% decline year-over-year. Fourth quarter gross margin of 63.1% and gross profit decline of 7% year-over-year. Full year revenue of $288.4 million, representing 15% growth year-over-year. Full year gross margin of 66.7% and gross profit growth of 8% year-over-year. Active Buyers of 1.7 million and Orders of 1.5 million in Q4 2022, representing year-over-year declines of 2% and 8%, respectively. Record annual orders of 6.5 million, representing growth of 22% year-over-year. Reached 42 Resale-as-a-Service (RaaS) brand clients by year-end 2022, and continuing to expand the program in 2023 with J. Crew, kate spade new york, and francesca’s.OAKLAND, Calif., March 06, 2023 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP), one of the largest online resale platforms for apparel, shoes,...

Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6% Completed First Surgeries and Initiated Limited Market Release of New RevoMotion™ Reverse Shoulder Arthroplasty System Commenced Full Market Release of X-Twist™ Fixation System in Sports Medicine Hyalofast®, Anika’s Off-the-Shelf Single-Stage Cartilage Repair Product, Designated as a Breakthrough Device by FDA; Pivotal Phase III Clinical Trial Approaching Full Enrollment, with 199 Enrolled out of 200 Engaging with FDA Regarding Next Steps for Regulatory Approval of Cingal®, Anika’s Next Generation, Non-Opioid, Single-Injection Product to Treat Short and Long-Term OA Pain BEDFORD, Mass., March 06, 2023 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics,...

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Expect to Report Initial Data from Oral Plogosertib 140-101 Dose Escalation – – Management to Host Conference Call at 4:30 pm ET Today – BERKELEY HEIGHTS, N.J., March 06, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2022 financial results and provided a business update. “After a productive 2022, we anticipate that 2023 will be even more exciting for Cyclacel. We plan to advance...

First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected in mid-2023, initial Phase 1 PD modeling and additional PK and safety data expected in 2H 2023, recommended phase 2 dose and additional safety data expected in mid-2024 Continued progress in oncology pipeline – on track to file IND for IMM-6-415 in Q4 2023 Cash runway extended into Q4 2024; sharpened focus on oncology pipeline and suspension of discovery-stage neuroscience programs Conference call and webcast today at 4:30 p.m. ET. CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...

Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 millionFY 2023 revenue guidance range $95-98 million MARLBOROUGH, Mass., March 06, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2022. “Akoya’s strong performance in 2022 is a reflection of the robust demand for our leading spatial biology solutions, our thoughtful consideration of market requirements, and sound execution of our financial and strategic plan,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. “The accelerating adoption of our solutions enabled record setting revenues quarter over quarter throughout the year. We grew our installed base to 934 instruments by year end 2022 and expanded our reagent...